SC
GPCR icon

SummitTX Capital’s Structure Therapeutics GPCR Stock Holding History

SummitTX Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-94,671
Closed -$6.58M – 856
2025
Q4 		$6.58M Buy
+94,671
New +$3.87M 0.2% 122

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SummitTX Capital's GPCR Position: Q1 2026 in Review

SummitTX Capital sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 94,671 shares — an estimated $6.58M sold.

SummitTX Capital first reported a position in GPCR in Q4 2025 and held it in 1 quarter. The position peaked at $6.58M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • SummitTX Capital reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SummitTX Capital sold 94,671 Structure Therapeutics shares in Q1 2026, an estimated $6.58M.
  • SummitTX Capital first reported a position in Structure Therapeutics in Q4 2025 and held it in 1 quarter.
  • SummitTX Capital's Structure Therapeutics position peaked at $6.58M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.